Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classifica tra le azioni #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Prezzo delle azioni
$0.00185055
Capitalizzazione di mercato
$48.29K
Variazione (1 giorno)
-3.55%
Variazione (1 anno)
30.31%
Paese
GB
Scambia Nuformix plc (NFX)

Categoria

Healthcare
Ricavi di Nuformix plc (NFX)
Ricavi nel Mar 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Nuformix plc, i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2024, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2023, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Nuformix plc da 2014 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH